Devices and Wearables Library
Every article, presentation, spotlight, and news item we've tagged to Devices and Wearables.
Showing 25–48 of 59
Home EEG Sleep Monitoring Achieves Clinical-Grade Accuracy
Integration of at-home EEG sleep monitoring into decentralized clinical trials enables objective measurement of sleep architecture with 88-96% agreement to laboratory polysomnography. This addresses a critical measurement gap in CNS studies where sleep quality directly influences neurological outcomes and therapeutic response.
Seveno backs PointFit wearable patch
Seveno Capital's investment in PointFit reflects a market shift toward direct biochemical monitoring via wearable patches that measure lactate and other sweat biomarkers in real time. Continuous metabolic substrate tracking—rather than behavioral proxies like step count—provides actionable insight into energy dynamics, recovery debt, and metabolic flexibility relevant to both performance optimization and early detection of metabolic decline.
Home EEG Detects Cognitive Decline Before Clinic Tests
An at-home EEG headset paired with cognitive tasks detected early speech and facial-expression changes in ALS patients over eight months—shifts that standard clinic-based testing missed. The platform demonstrated high usability and data quality among people with severe motor impairment, addressing a critical gap in how cognitive and behavioral decline are tracked in neurodegenerative disease.
Wearable startup Temple secures $54m for brain monitoring
Temple, a wearable startup backed by former Zomato CEO Deepinder Goyal, has raised $54 million to develop a temple-worn device that continuously monitors cerebral blood flow. The device represents a shift in performance monitoring from peripheral metrics like heart rate to direct measurement of brain perfusion during cognitive and physical demands.
Platform Over Hardware: How Google Health Shifts Wearable Economics
Google's redesign of Fitbit into Google Health repositions wearables as a data platform rather than a subscription product, leveraging AI-powered coaching to interpret health signals for users. This shift threatens the business models of standalone wearable companies by commoditizing their core tracking functions within a larger software ecosystem.
Beacon Biosignals upsizes Series B to more than $97 million
Beacon Biosignals raised $97 million in Series B extension funding to advance at-home EEG technology and AI-driven neural analytics for diagnostic and clinical applications. The capital supports commercialization of FDA-cleared wearable technology that captures real-world brain activity data for precision medicine.
NeuroRPM to provide AI monitoring for Annovis Parkinson’s trial
NeuroRPM's FDA-cleared wearable platform will continuously monitor motor symptoms in a 500-participant Parkinson's disease trial, using Apple Watch data to measure bradykinesia, tremor, and dyskinesia with algorithmic precision. This represents the first FDA-cleared AI device for real-world Parkinson's symptom tracking, enabling detection of treatment response at granularity not achievable through standard clinical assessments alone.
Symptom-triggered ECG doubles arrhythmia detection versus standard monitors
A 350-patient study comparing handheld ECG devices to standard hospital monitors found that symptom-triggered recordings with a palm-sized device detected arrhythmias nearly twice as often as conventional 24–48-hour monitors and outperformed continuous patch monitors by a factor of 2.5. Early detection of silent arrhythmias like atrial fibrillation reduces stroke risk and accelerates treatment decisions.
From wrist data to lifespan: elucidating inflammation-driven biological aging via activity rhythms captured by wearable devices
Wearable devices tracking activity rhythms reveal that irregular movement patterns correlate with systemic inflammation and accelerated biological aging. This connection between circadian disruption and aging rate offers a quantifiable marker for longevity risk that precedes clinical disease.
Unified Cardiometabolic Monitoring Closes Fragmented Diabetes Care Gap
Diathrive and AliveCor's partnership integrates diabetes and cardiovascular monitoring into a single platform, addressing the clinical reality that these conditions are physiologically linked yet typically managed in isolation. This integration targets employers seeking to reduce cardiometabolic risk through coordinated early detection rather than reactive disease management.
Epia Neuro debuts with stroke-focused BCI
Epia Neuro has launched an implantable brain-computer interface designed to help stroke survivors translate neural intent into functional movement through assistive devices. The approach prioritizes practical restoration of independence in daily life rather than speculative enhancement, addressing a significant gap in post-stroke rehabilitation where functional disability persists across years or decades.
HPV Self-Testing Expands Cervical Cancer Prevention Access
Self-collected HPV testing at home offers a practical alternative to clinical Pap smears, potentially improving screening adherence by removing barriers to access and reducing friction in cervical cancer prevention. This shift from provider-administered to patient-directed screening represents a meaningful change in how early detection can reach broader populations.
Nocturnal tumescence as cardiovascular biomarker
Emagene.life and Adam Health partnered to distribute the Adam Sensor—a device measuring nocturnal penile tumescence as a biomarker—across Malaysia and Singapore, integrated with AI interpretation to guide personalized health protocols. Nocturnal penile tumescence correlates with cardiovascular, hormonal, and metabolic function, making it a proxy for systemic health status in men.
Fitbit founders put family first in new health monitoring startup
Luffu, a new app from Fitbit co-founders Park and Friedman, monitors collective family health by tracking changes in individual rhythms over time through integrated data from devices, medical records, and daily observations. The product addresses evidence that strong family relationships provide physiological protection comparable to major lifestyle interventions, integrating relational health into the longevity conversation.
ŌURA builds health AI stack with its latest acquisition spree
Ōura is assembling a health AI infrastructure platform through strategic acquisitions—integrating wearable data, metabolic tracking, clinical records, and performance analytics into a unified system designed to convert fragmented health signals into actionable guidance. This shift from passive tracking to real-time, AI-driven interpretation represents a fundamental change in how consumer health data could be organized and applied to longevity optimization.
Well Health partners with AliveCor for cardiologist review
Well Health and AliveCor have integrated Canadian cardiologist review into the Kardia mobile ECG platform, enabling users to obtain physician-evaluated cardiac assessments within 24 hours. This addresses extended specialist wait times while maintaining clinical oversight of AI-detected arrhythmias and cardiac conditions.
WELL Health partners with AliveCor for cardiac monitoring in Canada
WELL Health has integrated Canadian cardiologists into AliveCor's Kardia platform to provide physician-reviewed ECG interpretation within 24 hours, addressing documented gaps in cardiology access where wait times have risen 53% nationally. This partnership combines AI-powered arrhythmia detection with human clinical validation to expand remote cardiac monitoring capacity.
Microsensor for glucose monitoring hits world-first 10-day milestone
Sava Technologies has demonstrated a minimally invasive microsensor that continuously monitors glucose for 10 days with accuracy comparable to traditional continuous glucose monitors, while requiring a filament roughly 10 times shorter and causing substantially less tissue disruption. This advance addresses a critical adoption barrier in glucose monitoring, where discomfort and skin irritation have limited consistent use despite established clinical benefits.
EEG Software Maps Cognitive Processing Before Clinical Decline
VoxNeuro received FDA 510(k) clearance for software that analyzes brain electrical activity through standardized cognitive tasks, providing clinicians with quantified measures of neural function against a reference database of nearly 20,000 healthy adult data points. The tool supports assessment of cognitive processing without delivering diagnosis, positioning it as an objective biomarker for brain function relevant to early detection and monitoring.
Turning your bed into a preventive health platform
Eight Sleep's Pod smart mattress uses continuous biometric monitoring during sleep—tracking heart rate, heart rate variability, and breathing patterns—to shift from reactive treatment to predictive intervention. The company's $1.5 billion valuation reflects a strategic thesis that sleep represents both a high-frequency measurement window and an actionable intervention point for longevity and early disease detection.
Continuous Hormonal Monitoring Reveals Gaps in Annual Testing
Continuous hormonal monitoring through wearable technology may address a fundamental gap in women's healthcare: the inadequacy of annual or biannual blood tests to capture hourly hormonal fluctuations. This shift from static snapshots to dynamic tracking could reveal patterns that isolated clinical measurements systematically miss, particularly during perimenopause and across reproductive transitions.
SpectraCell packages longevity, early disease detection in one kit
SpectraCell's Baseline Nexus bundles four diagnostic tests—micronutrient status, lipoprotein particle profiling, telomere length, and MTHFR genotyping—into a single assessment designed to identify subclinical dysfunction before it progresses to clinical disease. The package reframes preventive diagnostics by measuring intracellular nutrient utilization and biological aging markers alongside conventional cardiovascular risk factors, enabling earlier intervention at the stage where metabolic and inflammatory processes are still modifiable.
Osteoboost raises $8m to scale bone wearable
Osteoboost has secured $8 million in funding to scale an FDA-cleared wearable device that delivers calibrated vibration therapy to address osteopenia, a condition affecting 44 million Americans currently managed with minimal intervention. The device represents a regulated approach to early-stage bone loss prevention in a market where pharmacological treatment remains absent and diagnostic management remains largely passive.
Data without decisions: Why biomarkers alone fail
Wearable technology and biomarker testing provide detailed health data, but information alone does not drive behavior change. Effective health optimization requires prioritized decision-making and strategic intervention selection, not data accumulation.